You make a valid point. When we look at the review and evaluation of products, it's really important that we look at all aspects. So part of the regulatory process really focuses on the human health component as well as the animal health component. That is our mandate, when we look at Health Canada and the way we review and evaluate drugs.
I would like to be very specific, in that the review and evaluation is really based on sound science decisions. And if the information in a data submission points to the fact that there are issues with respect to human health and appropriate use of the drugs, and if there can be any risk management strategies that can be put in place to be able to manage the product appropriately, then Health Canada is obligated to make a decision on how to move that forward.